drugset / Trial / NCT06348264
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Phase 2
Recruiting
37 enrolled
Peking University First Hospital
Beijing Biote Pharmaceutical Co.,Ltd · collabJiangsu Hengrui Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC). The procedures include screening, treatment and follow-up period. The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist (LHRHa) for up to 2 years.
Timeline
- Start
- 2024-10-10
- Primary completion
- 2029-03-30
- Completion
- 2031-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rezvilutamide | Unknown | 240 mg | Oral |
| Background | Leuprolide | Other / unclassified | — | — |